Management of Confirmed Hyperkalemia in an 81-Year-Old Woman on Losartan
Do not discontinue losartan; instead, implement dietary potassium restriction, add a loop diuretic if not contraindicated, and consider a potassium binder to maintain this cardioprotective medication.
Classification and Risk Assessment
This patient has moderate hyperkalemia (5.6 mmol/L, confirmed on repeat testing), which falls in the 5.5-6.0 mEq/L range 1. At this level, she is at risk for cardiac arrhythmias, though life-threatening events are less common at potassium <6.0 mEq/L, particularly in patients with chronic conditions like diabetes 1.
Key Risk Factors Present:
- Advanced age (81 years) - increases hyperkalemia risk 1
- Losartan (ARB) - directly causes hyperkalemia by reducing aldosterone 1, 2
- Likely diabetes (on metformin) - increases risk 1
- Possible chronic kidney disease - common in this demographic with diabetes and hypertension 1
Immediate Actions
1. Obtain ECG and Additional Labs
- Check ECG for conduction abnormalities (widened QRS, peaked T waves, loss of P waves) 1
- Measure creatinine/eGFR to assess renal function 2
- Rule out pseudo-hyperkalemia (hemolysis during blood draw) 1
- Check for metabolic acidosis 1
2. Review All Medications
Beyond losartan and metformin, identify:
- NSAIDs (including over-the-counter ibuprofen) - major contributor 1, 2
- Potassium supplements or salt substitutes 1
- Other potassium-raising drugs: beta-blockers, trimethoprim-sulfamethoxazole, potassium-sparing diuretics 1
Critical caveat: The combination of losartan with NSAIDs significantly increases hyperkalemia risk and can cause acute kidney injury 2. If the patient is taking NSAIDs, discontinue them immediately.
Treatment Strategy
Step 1: Preserve RAASi Therapy (Losartan)
Do not discontinue or reduce losartan dose initially 1. RAASi therapy reduces mortality and morbidity in patients with cardiovascular disease, hypertension, and diabetes 1. The 2025 European guidelines emphasize that reducing recurrence risk should be standard practice, and all healthcare providers should work to enable continued RAASi therapy 3.
Step 2: Implement Conservative Measures
Dietary Modifications:
- Reduce non-plant sources of potassium (meat, dairy) rather than blanket restriction 4
- Avoid high-potassium foods: bananas, melons, orange juice, salt substitutes 1
- Recent evidence questions aggressive dietary restriction effectiveness 4
Add Loop Diuretic:
- Initiate furosemide (e.g., 20-40 mg daily) to increase renal potassium excretion 1
- This is particularly effective if the patient has any volume overload or is not already on diuretic therapy
Correct Metabolic Acidosis (if present):
Step 3: Consider Potassium Binders
Given confirmed, persistent hyperkalemia at 5.6 mmol/L on two occasions, initiate a potassium binder to prevent recurrence and maintain losartan therapy 3, 5, 6:
Preferred options:
- Patiromer or sodium zirconium cyclosilicate (SZC) - newer agents with better safety profiles 1, 5, 6
- These have demonstrated efficacy in clinical trials and real-world evidence shows reduced hospitalizations and medical costs 6
Avoid:
- Sodium polystyrene sulfonate (SPS) has limited controlled evidence and carries warnings for severe gastrointestinal adverse events 1, 6
Step 4: Monitoring Protocol
Initial monitoring (first 1-2 weeks):
- Recheck potassium within 3-7 days after interventions
- Monitor renal function (creatinine/eGFR)
Long-term monitoring:
- Potassium levels every 1-3 months depending on stability 3
- After normalization with a potassium binder, additional monitoring beyond routine comorbidity management is not necessary 3
Common Pitfalls to Avoid
Prematurely discontinuing losartan: This increases cardiovascular risk and mortality 1. Down-titration or discontinuation should be a last resort after other measures fail.
Missing concurrent NSAIDs: The FDA label explicitly warns about the combination of losartan with NSAIDs causing hyperkalemia and renal dysfunction 2. Always ask about over-the-counter medications.
Ignoring recurrence risk: This patient has confirmed hyperkalemia on two occasions, indicating chronicity. Without intervention, 50% of patients with cardiovascular disease and CKD have ≥2 recurrences within 1 year 1. Proactive prevention is essential 3.
Relying solely on dietary restriction: Evidence supporting dietary potassium restriction effectiveness is lacking 4. Use it as an adjunct, not primary therapy.
Not checking for dual RAAS blockade: Ensure the patient is not on an ACE inhibitor plus losartan, which increases hyperkalemia risk substantially 2.
Algorithm Summary
Confirmed K+ 5.6 mmol/L on losartan
↓
1. ECG + labs (creatinine, rule out pseudo-hyperkalemia)
2. Medication review → STOP NSAIDs if present
3. DO NOT stop losartan
4. Add furosemide 20-40 mg daily
5. Dietary counseling (reduce non-plant K+ sources)
6. Initiate potassium binder (patiromer or SZC)
7. Recheck K+ in 3-7 days
8. Long-term monitoring every 1-3 monthsThis approach prioritizes maintaining cardioprotective therapy while actively managing hyperkalemia to reduce morbidity and mortality 3, 1, 6.